Category: MS Relapse-Exacerbation

Featured image for “How to Spot the Signs of an MS Flare”

How to Spot the Signs of an MS Flare

When new multiple sclerosis symptoms crop up or old ones worsen, you may be having an MS relapse. By Chris…

Stuart Schlossman

What to Expect From an MS Relapse

 What can you expect from a Multiple Sclerosis relapse? Let’s take a look at one young Black woman’s personal journey…

Stuart Schlossman

What is a Multiple Sclerosis Pseudo-exacerbation?

Click the video box to watch this very well presented program Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…

Stuart Schlossman

MS Relapse: 6 Things to Do During a Flare-Up

 Multiple sclerosis (MS) can be unpredictable. About 85 percent of people with MS are diagnosed with relapsing-remitting MS (RRMS), which is characterized…

Stuart Schlossman

Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

  Abstract Background: Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405),…

Stuart Schlossman

video: Learn about MS Brain Health, Stress & Wellness with a Q&A plus a separate Q&A on the COVID Vaccines

Click image to watch  Click HERE to Subscribe for the MS Beacon eNewsletter Visit our MS Learning Channel on YouTube:…

Stuart Schlossman

Demyelinating Plaques: A Cause of Trigeminal Neuralgia Secondary to MS

February 2, 2021 Click HERE to Subscribe for the MS Beacon Newsletter Study investigators systematically collected clinical characteristics and neuroanatomical…

Stuart Schlossman

Rituximab More Effective Than Gilenya, Tecfidera, and Comparable to Tysabri, Study Finds

AUGUST 11, 2020   BY MARTA FIGUEIREDO   Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod) and Tecfidera (dimethyl…

Stuart Schlossman

Siponimod Reduces Risk of Disability Progression Regardless of Prior Relapses in MS

Data from the phase 3 EXPAND clinical trial (NCT01665144) of siponimod (Mayzent; Novartis) demonstrated the treatment’s ability to reduce the…

Stuart Schlossman

RSVP to join us on May 26th for THE MS Summit , a Virtual MS educational event

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…

Stuart Schlossman

Categories

Latest Blog Posts